Edward A. Copelan

11.1k total citations · 1 hit paper
194 papers, 5.7k citations indexed

About

Edward A. Copelan is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Edward A. Copelan has authored 194 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Hematology, 54 papers in Oncology and 52 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Edward A. Copelan's work include Hematopoietic Stem Cell Transplantation (81 papers), Acute Myeloid Leukemia Research (69 papers) and Acute Lymphoblastic Leukemia research (49 papers). Edward A. Copelan is often cited by papers focused on Hematopoietic Stem Cell Transplantation (81 papers), Acute Myeloid Leukemia Research (69 papers) and Acute Lymphoblastic Leukemia research (49 papers). Edward A. Copelan collaborates with scholars based in United States, Canada and United Kingdom. Edward A. Copelan's co-authors include Matt Kalaycio, Brian J. Bolwell, Hillard M. Lazarus, Ronald Sobecks, Belinda R. Avalos, Lisa Rybicki, Mikkael A. Sekeres, Robert M. Dean, Brad Pohlman and Anjali S. Advani and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Edward A. Copelan

177 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hematopoietic Stem-Cell Transplantation

2006 1.8k citations Edward A. Copelan profile →

Peers

Edward A. Copelan

HEMAT

ONCOL

PHEOH

IMMUN

GENET

Christopher Bredeson Canada

Frédéric Baron Belgium

Madan Jagasia United States

Marcelo C. Pasquini United States

Hans A. Messner Canada

Mahmoud Aljurf Saudi Arabia

Andrew Artz United States

Michael A. Pulsipher United States

Kirk R. Schultz Canada

Yves Chalandon Switzerland

Christopher Bredeson Canada

Edward A. Copelan

4.5k ×1.2

HEMAT

1.9k ×1.3

ONCOL

1.6k ×1.2

PHEOH

1.0k ×1.0

IMMUN

1.3k ×1.4

GENET

Citations per year, relative to Edward A. Copelan Edward A. Copelan (= 1×) peers Christopher Bredeson

Countries citing papers authored by Edward A. Copelan

Since Specialization

Citations

This map shows the geographic impact of Edward A. Copelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward A. Copelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward A. Copelan more than expected).

Fields of papers citing papers by Edward A. Copelan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward A. Copelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward A. Copelan. The network helps show where Edward A. Copelan may publish in the future.

Co-authorship network of co-authors of Edward A. Copelan

This figure shows the co-authorship network connecting the top 25 collaborators of Edward A. Copelan. A scholar is included among the top collaborators of Edward A. Copelan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward A. Copelan. Edward A. Copelan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vaidya, Rakhee, Hamid Ehsan, Tamara K. Moyo, et al.. (2024). Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma. Transplantation and Cellular Therapy. 30(11). 1082.e1–1082.e10. 4 indexed citations

Arnall, Justin, et al.. (2024). Venous Thromboembolism Incidence and Risk Factors in Patients Undergoing Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 31(2). 111.e1–111.e10. 2 indexed citations

Hamilton, Betty K., Lisa Rybicki, Hong Li, et al.. (2023). Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention. Blood Advances. 7(16). 4505–4513. 4 indexed citations

Knight, Thomas G., Danielle Boselli, Jing Ai, et al.. (2023). Enhanced Support Services Including Nurse Navigation Mitigate Socioeconomic Disparities in the Treatment of Patients with Acute Lymphoblastic Leukemia. Blood. 142(Supplement 1). 5078–5078. 1 indexed citations

Foureau, David, Fei Guo, Nury Steuerwald, et al.. (2023). Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy. Experimental Hematology. 129. 104125–104125. 1 indexed citations

Knight, Thomas G., Myra Robinson, Jing Ai, et al.. (2022). Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy. JCO Oncology Practice. 18(9). e1494–e1504. 43 indexed citations

Knight, Thomas G., Myra Robinson, Michael R. Grunwald, et al.. (2018). Patient Reported Financial Toxicity in Acute Leukemia. Blood. 132(Supplement 1). 4796–4796. 9 indexed citations

Robinson, Myra, Shebli Atrash, Jared Block, et al.. (2017). Prognostic Significance of Ki67 Expression By Immunohistochemistry (IHC) on Bone Marrow Biopsy in Newly Diagnosed Multiple Myeloma. Blood. 130. 4348–4348.

Khouri, Jack, Lisa Rybicki, Navneet S. Majhail, et al.. (2017). Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. Journal of Clinical Apheresis. 33(3). 303–309. 6 indexed citations

10.

Copelan, Edward A., et al.. (2017). Recent advances in hematopoietic cell transplantation in myelodysplastic syndrome.. PubMed. 24(130). 51–57. 1 indexed citations

11.

Bhutani, Manisha, David Foureau, Qing Zhang, et al.. (2017). Peripheral Cellular Immunome Reveals Heterogeneity Spanning Myeloma Spectrum Diseases. Blood. 130. 3054–3054. 2 indexed citations

12.

Foureau, David, Manisha Bhutani, Qing Zhang, et al.. (2017). Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma. Blood. 130. 1817. 1 indexed citations

13.

Grunwald, Michael R., Danielle Boselli, Lauren Bohannon, et al.. (2017). Frontline Azacitidine As a Bridge to Allogeneic Transplantation in Acute Myeloid Leukemia. Blood. 130. 3864–3864. 2 indexed citations

14.

Atrash, Shebli, Myra Robinson, Qing Zhang, et al.. (2017). Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma. Blood. 130. 1779–1779. 1 indexed citations

15.

Patel, Jai N., Issam S. Hamadeh, Qing Zhang, et al.. (2017). Busulfan Pharmacogenetics and Drug Exposure in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation. Blood. 130. 3215–3215. 1 indexed citations

16.

Hamilton, Betty K., Lisa Rybicki, Steven Andrèsen, et al.. (2015). Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer. Hematology/Oncology and Stem Cell Therapy. 8(3). 115–124. 2 indexed citations

17.

Copelan, Edward A., Michael R. Grunwald, Lawrence J. Druhan, & Belinda R. Avalos. (2015). Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics. Hematology/Oncology and Stem Cell Therapy. 8(4). 143–149. 2 indexed citations

18.

Sekeres, Mikkael A., Paul Elson, Matt Kalaycio, et al.. (2008). Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 113(1). 28–36. 146 indexed citations

19.

Mahindra, Anuj, Brian J. Bolwell, Ronald Sobecks, et al.. (2008). Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma. Biology of Blood and Marrow Transplantation. 14(11). 1239–1244. 36 indexed citations

20.

Farag, Sherif S., Patrick Elder, Guido Marcucci, et al.. (2003). Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged ≥50 years compared to younger adults with low-risk disease. Bone Marrow Transplantation. 31(2). 87–93. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact